Yuanfeng Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuanfeng Liu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Hualong Bai
Department of Vascular and Endovascular Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications - Tao Bai
Department of Vascular and Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
2 shared publications - Yanfei Wang
Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, China
2 shared publications Chen Luan
School of Materials Science and Engineering, Tsinghua University, Beijing 100084, China
1 shared publicationChongyu Shao
College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China
1 shared publicationChui Zeng
Heart Center and Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, China
1 shared publication
Latest Publications
- 26 June 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158489
Discovery and characterization of hinokiflavone as a potent natural CD137 inhibitor for Kawasaki disease
- 26 June 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158489
Discovery and characterization of hinokiflavone as a potent natural CD137 inhibitor for Kawasaki disease
- 29 December 2025
- Published by Wiley in The FASEB Journal
- Vol. 40 (1) , e71378
Spatial Metabolomics Reveals GLA ‐Mediated Imbalance of Gal 2 Cer / GalCer as a Therapeutic Target in Myocardial Ischemia–Reperfusion Injury
Myocardial ischemia–reperfusion (I/R) injury, a major complication of reperfusion therapies for acute myocardial infarction that exacerbates myocardial necrosis, impairs cardiac function, and worsens patient prognosis. Profound metabolic disturbances drive myocardial I/R injury; however, their spatial heterogeneity remains unclear. Using MALDI mass spectrometry imaging with spatial segmentation, we mapped the spatiotemporal metabolite dynamics in mouse heart tissue across multiple time points (30 min ischemia to 7 days reperfusion), aiming to identify critical metabolic pathways and regulatory targets underlying I/R injury. Glycerophospholipids and sphingolipids exhibited pronounced heterogeneity. Glycerophospholipid metabolism remained dysregulated throughout the I/R process, with long‐chain phospholipids (PA, PE, PC, and PS) exhibiting a distinct distribution gradient. They were enriched in the remote zone, downregulated in the border zone, and markedly reduced in the injured zone 6 h post‐reperfusion. Sphingolipid metabolism was dynamically reprogrammed, with galactosylceramide (GalCer) accumulating and digalactosylceramide (Gal 2 Cer) depleting in injured and border zones. Mechanistically, α‐galactosidase (GLA), which hydrolyzes Gal2Cer to GalCer, was upregulated in the border zone post‐I/R. Functional validation further demonstrated that both cardiomyocyte‐specific GLA knockdown (via AAV‐shGla) and pharmacological inhibition (using the GLA inhibitor GR181413A) effectively reduced myocardial infarct size, alleviated pathological remodeling, and improved cardiac function in I/R‐injured mice. Collectively, our spatial metabolomics revealed that GLA‐mediated Gal2Cer/GalCer imbalance is a critical regulator of myocardial I/R injury, and targeting GLA represents a promising therapeutic strategy.
- 29 December 2025
- Published by Wiley in The FASEB Journal
- Vol. 40 (1) , e71378
Spatial Metabolomics Reveals GLA ‐Mediated Imbalance of Gal 2 Cer / GalCer as a Therapeutic Target in Myocardial Ischemia–Reperfusion Injury
Myocardial ischemia–reperfusion (I/R) injury, a major complication of reperfusion therapies for acute myocardial infarction that exacerbates myocardial necrosis, impairs cardiac function, and worsens patient prognosis. Profound metabolic disturbances drive myocardial I/R injury; however, their spatial heterogeneity remains unclear. Using MALDI mass spectrometry imaging with spatial segmentation, we mapped the spatiotemporal metabolite dynamics in mouse heart tissue across multiple time points (30 min ischemia to 7 days reperfusion), aiming to identify critical metabolic pathways and regulatory targets underlying I/R injury. Glycerophospholipids and sphingolipids exhibited pronounced heterogeneity. Glycerophospholipid metabolism remained dysregulated throughout the I/R process, with long‐chain phospholipids (PA, PE, PC, and PS) exhibiting a distinct distribution gradient. They were enriched in the remote zone, downregulated in the border zone, and markedly reduced in the injured zone 6 h post‐reperfusion. Sphingolipid metabolism was dynamically reprogrammed, with galactosylceramide (GalCer) accumulating and digalactosylceramide (Gal 2 Cer) depleting in injured and border zones. Mechanistically, α‐galactosidase (GLA), which hydrolyzes Gal2Cer to GalCer, was upregulated in the border zone post‐I/R. Functional validation further demonstrated that both cardiomyocyte‐specific GLA knockdown (via AAV‐shGla) and pharmacological inhibition (using the GLA inhibitor GR181413A) effectively reduced myocardial infarct size, alleviated pathological remodeling, and improved cardiac function in I/R‐injured mice. Collectively, our spatial metabolomics revealed that GLA‐mediated Gal2Cer/GalCer imbalance is a critical regulator of myocardial I/R injury, and targeting GLA represents a promising therapeutic strategy.
- Open Access
- 10 April 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (16) , 18083-18098
Exploring the Potential Mechanisms of Guanxinshutong Capsules in Treating Pathological Cardiac Hypertrophy based on Network Pharmacology, Computer-Aided Drug Design, and Animal Experiments
Cardiovascular diseases (CVDs) are significant causes of morbidity and mortality worldwide, and pathological cardiac hypertrophy (PCH) is an essential predictor of many heart diseases. Guanxinshutong capsule (GXST) is a Chinese patent medicine widely used in the clinical treatment of CVD, In our previous research, we identified 111 compounds of GXST. In order to reveal the potential molecular mechanisms by which GXST treats PCH, this study employed network pharmacology methods to screen for the active ingredients of GXST in treating PCH and predicted the potential targets. The results identified 26 active ingredients of GXST and 110 potential targets for PCH. Through a protein–protein interaction (PPI) network, gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, we confirmed AKT1, MAPK1, and MAPK3 as the core proteins in GXST treatment of PCH, thus establishing the PI3K/AKT and MAPK signaling pathways as the significant mechanisms of GXST in treating PCH. The results of molecular docking (MD) demonstrate that flavonoid naringenin and diterpenoid tanshinone iia have the highest binding affinity with the core protein. Before performing molecular dynamics simulations (MDSs), the geometric structure of naringenin and tanshinone iia was optimized using density functional theory (DFT) at the B97–3c level, and RESP2 atomic charge calculations were carried out at the B3LYP-D3(BJ)/def2-TZVP level. Further MDS results demonstrated that in the human body environment, the complex of naringenin and tanshinone iii with core proteins exhibited high stability, flexibility, and low binding free energy. Additionally, naringenin and tanshinone iia showed favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics and passed the drug similarity (DS) assessment. Ultrasound cardiograms and cardiac morphometric measurements in animal experiments demonstrate that GXST can improve the PCH induced by isoproterenol (ISO). Protein immunoblotting results indicate that GXST increases the expression of P-eNOS and eNOS by activating the PI3K/AKT signaling pathway and the MAPK signaling pathway, further elucidating the mechanism of action of GXST in treating PCH. This study contributes to the elucidation of the key ingredients and molecular mechanisms of GXST in treating PCH.
- 10 April 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (16) , 18083-18098
Open AccessExploring the Potential Mechanisms of Guanxinshutong Capsules in Treating Pathological Cardiac Hypertrophy based on Network Pharmacology, Computer-Aided Drug Design, and Animal Experiments
Cardiovascular diseases (CVDs) are significant causes of morbidity and mortality worldwide, and pathological cardiac hypertrophy (PCH) is an essential predictor of many heart diseases. Guanxinshutong capsule (GXST) is a Chinese patent medicine widely used in the clinical treatment of CVD, In our previous research, we identified 111 compounds of GXST. In order to reveal the potential molecular mechanisms by which GXST treats PCH, this study employed network pharmacology methods to screen for the active ingredients of GXST in treating PCH and predicted the potential targets. The results identified 26 active ingredients of GXST and 110 potential targets for PCH. Through a protein–protein interaction (PPI) network, gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, we confirmed AKT1, MAPK1, and MAPK3 as the core proteins in GXST treatment of PCH, thus establishing the PI3K/AKT and MAPK signaling pathways as the significant mechanisms of GXST in treating PCH. The results of molecular docking (MD) demonstrate that flavonoid naringenin and diterpenoid tanshinone iia have the highest binding affinity with the core protein. Before performing molecular dynamics simulations (MDSs), the geometric structure of naringenin and tanshinone iia was optimized using density functional theory (DFT) at the B97–3c level, and RESP2 atomic charge calculations were carried out at the B3LYP-D3(BJ)/def2-TZVP level. Further MDS results demonstrated that in the human body environment, the complex of naringenin and tanshinone iii with core proteins exhibited high stability, flexibility, and low binding free energy. Additionally, naringenin and tanshinone iia showed favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) characteristics and passed the drug similarity (DS) assessment. Ultrasound cardiograms and cardiac morphometric measurements in animal experiments demonstrate that GXST can improve the PCH induced by isoproterenol (ISO). Protein immunoblotting results indicate that GXST increases the expression of P-eNOS and eNOS by activating the PI3K/AKT signaling pathway and the MAPK signaling pathway, further elucidating the mechanism of action of GXST in treating PCH. This study contributes to the elucidation of the key ingredients and molecular mechanisms of GXST in treating PCH.
- 27 March 2023
- Published by Springer Nature in Nuclear Science and Techniques
- Vol. 34 (3) , 1-11
Material decomposition of spectral CT images via attention-based global convolutional generative adversarial network
- 27 March 2023
- Published by Springer Nature in Nuclear Science and Techniques
- Vol. 34 (3) , 1-11
Material decomposition of spectral CT images via attention-based global convolutional generative adversarial network
- 10 October 2021
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 79, 139-144
Nonatheromatous Popliteal Artery Disease
- 10 October 2021
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 79, 139-144
Nonatheromatous Popliteal Artery Disease
- 13 April 2021
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 55 (8) , 851-855
In Situ Laser Fenestration for Delayed Left Subclavian Artery Revascularization Following Thoracic Endovascular Aortic Repair of Type B Aortic Dissection
In situ laser fenestration (ISLF) is currently used to reconstruct the aortic major branches during thoracic endovascular aortic repair (TEVAR). To our knowledge, there have been no reports on the application of ISLF for delayed revascularization of the LSA previously sealed in TEVAR. This report describes 5 patients who underwent ISLF for delayed LSA revascularization, with a technical success rate of 80%. No endoleakage occurred, and stents remained patent during more than 6-month follow-up. ISLF is an effective, safe and minimally invasive method for delayed revascularization of the LSA following TEVAR for type B aortic dissection (TBAD) when patients are selected appropriately.
- 13 April 2021
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 55 (8) , 851-855
In Situ Laser Fenestration for Delayed Left Subclavian Artery Revascularization Following Thoracic Endovascular Aortic Repair of Type B Aortic Dissection
In situ laser fenestration (ISLF) is currently used to reconstruct the aortic major branches during thoracic endovascular aortic repair (TEVAR). To our knowledge, there have been no reports on the application of ISLF for delayed revascularization of the LSA previously sealed in TEVAR. This report describes 5 patients who underwent ISLF for delayed LSA revascularization, with a technical success rate of 80%. No endoleakage occurred, and stents remained patent during more than 6-month follow-up. ISLF is an effective, safe and minimally invasive method for delayed revascularization of the LSA following TEVAR for type B aortic dissection (TBAD) when patients are selected appropriately.
- 1 November 2020
- Published by Elsevier in Composites Part A: Applied Science and Manufacturing
- Vol. 138, 106063
High strength and high ductility copper matrix composite reinforced by graded distribution of carbon nanotubes
- 1 November 2020
- Published by Elsevier in Composites Part A: Applied Science and Manufacturing
- Vol. 138, 106063
High strength and high ductility copper matrix composite reinforced by graded distribution of carbon nanotubes
- 1 December 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 91-94
A Novel OCR Approach Based on Document Layout Analysis and Text Block Classification
Document layout helps users to focus on important content of the documents while neglecting the rest whenever possible. This paper presents a novel Optical Character Recognition (OCR) algorithm whose performance is enhanced by post-processing based on information collected from document layout analysis. Initial OCR results are used for text block classification, whose results are then used to fine-tune the final results. Experimental results show that it outperforms the start-of-the-art OCR algorithms.
- 1 December 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 91-94
A Novel OCR Approach Based on Document Layout Analysis and Text Block Classification
Document layout helps users to focus on important content of the documents while neglecting the rest whenever possible. This paper presents a novel Optical Character Recognition (OCR) algorithm whose performance is enhanced by post-processing based on information collected from document layout analysis. Initial OCR results are used for text block classification, whose results are then used to fine-tune the final results. Experimental results show that it outperforms the start-of-the-art OCR algorithms.